· All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centers · Randomized, controlled Phase IIb trial evaluating TolerogenixX’s proprietary MIC technology, a first-in-class immune tolerance-inducing cell therapy, in living-donor kidney transplantation · Designed to address one of transplantation’s key issues: lifelong systemic immunosuppression · Key milestone in the clinical development of MIC-Lx and TolerogenixX’s proprietary MIC technology platform
June 29, 2026
· 1 min read
